Blog → Phenobarbital vs. Benzos for Alcohol Withdrawal

Phenobarbital vs. Benzos for Alcohol Withdrawal

Listen to this article
0:00 –:–

Written by Shannon Markus

Spoon Feed
Phenobarbital administration for alcohol withdrawal was associated with lower admission rates, shorter ED length of stay (LOS), and fewer IV medication administrations when compared to benzodiazepines.

Phenobarbital edges out benzos
Alcohol use disorder affects approximately 29% of U.S. adults, and nearly 50% of individuals with chronic alcohol use develop alcohol withdrawal syndrome (AWS). AWS accounts for an estimated 0.28% of all emergency department (ED) visits—roughly 400,000 encounters annually—and contributes to ED overcrowding, boarding, and increased hospital utilization. Although benzodiazepines remain the standard treatment, their limitations have driven interest in phenobarbital, which offers longer-acting GABAergic and anti-glutamatergic effects. Evidence guiding ED phenobarbital use is limited.

In this retrospective cohort study of 777 ED AWS encounters from 2020–2023, patients were categorized by treatment strategy: phenobarbital-only, benzodiazepine-only, or combination therapy. Phenobarbital monotherapy was associated with significantly lower hospital admission rates (52.1% vs. 74.0% for benzodiazepines) and shorter ED LOS (median 5.8 h vs. 7.0–10.3 h). Return visits within 72 hours (11.6%) and 30 days (20.8%) did not significantly differ by treatment group. Overall, phenobarbital monotherapy demonstrated operational advantages without compromising safety.

How does this change my practice?
A few years ago, my hospital system (which includes hundreds of hospitals across the country) switched to a phenobarbital-centric AWS protocol. The push came from studies highlighting its predictable pharmacokinetics, long half-life, and built-in auto-taper, which cuts down on the need for discharge tapers. Since I trained in an era when barbiturates were hardly used in the ED, it’s taken me awhile to fully get on board. This study adds to the growing evidence supporting phenobarbital for AWS, and it’s reassuring for me to see that it not only improves the patient experience, but also helps with ED flow and operations.

Source
Fewer Admissions, Shorter Stays: Phenobarbital Use for Alcohol Withdrawal in the Emergency Department. Acad Emerg Med. 2025 Oct 28. doi: 10.1111/acem.70170. Epub ahead of print. PMID: 41147831.

View Critical Appraisal

Critical Appraisal

Title: Fewer Admissions, Shorter Stays: Phenobarbital Use for Alcohol Withdrawal in the Emergency Department.
Background: Alcohol withdrawal syndrome significantly impacts ED resource utilization. While benzodiazepines are standard treatment, phenobarbital is being explored as an alternative due to potential advantages in symptom control and fewer redoses.
Study Question: Does phenobarbital monotherapy improve ED operational outcomes for AWS compared to benzodiazepines or combination therapy?
Study Design: Single-center, retrospective cohort study.
Population: 1178 adults treated for AWS in the ED at a regional academic medical center from January 1, 2020, to December 31, 2023.
Intervention: Phenobarbital monotherapy.
Comparison: Benzodiazepine monotherapy or combination therapy with phenobarbital and benzodiazepines.
Primary Outcome: Hospital admission rates.
Secondary Outcomes: ED length of stay, return visits within 72 hours, and 30-day hospital readmission.
Key Statistics: Admission rates: 74.0% for benzodiazepine-only, 62.4% for combination therapy, 52.1% for phenobarbital-only (OR 0.44, 95% CI 0.30–0.66, p < 0.0001). Median ED LOS: 5.8 hours for phenobarbital-only, 7.6 hours for benzodiazepine-only, 10.3 hours for combination therapy (p < 0.0001).
Results: Phenobarbital monotherapy was associated with significantly lower admission rates and shorter ED length of stay compared to benzodiazepine-based regimens.
Risk of Bias – Newcastle-Ottawa Scale:
  • Selection of Participants: Retrospective design may introduce selection bias.
Take Home: Phenobarbital may be a more efficient option for managing AWS in the ED, reducing admissions and ED stay duration.

Leave a Reply